115 results
Page 4 of 6
6-K
EX-99.2
1c7gqvsm
10 Dec 20
Current report (foreign)
6:03am
6-K
EX-99.1
l3n1kw0y27k 1h5
24 Nov 20
Current report (foreign)
6:03am
6-K
EX-99.1
e1ieuuec3h5osezd
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.2
kokcvszct9np3jxsbjf
16 Nov 20
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
6:39am
6-K
EX-99.1
p5wwrm
9 Nov 20
ObsEva appoints Brian O’Callaghan as Chief Executive Officer
7:32am
424B5
mb3ni
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
EX-99.1
i2qbn54 ev
14 Aug 20
Current report (foreign)
4:24pm
6-K
EX-99.2
yf5p08wb8
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.3
xhvy7ug di3p
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.1
w1xpqtsu43c2
7 Jul 20
Current report (foreign)
3:39pm
6-K
EX-99.1
9vnlficos4po9j
6 Jul 20
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
6:18am
6-K
EX-99.1
1smnj8lsfo
1 Jul 20
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
6:15am
6-K
EX-99.1
akyvzd16
4 Jun 20
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
6:11am
6-K
EX-99.2
oe3awv092dqo qz6nqnq
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.3
2sdvueq
5 May 20
Index to Unaudited Condensed Consolidated Financial Statements
6:01am
6-K
EX-99.1
vb4 wm4vftp17nw9ycx
23 Mar 20
ObsEva Provides Update Related to COVID-19 Pandemic
4:00pm
6-K
67ji4g4d8o8
15 Jan 20
Current report (foreign)
8:35pm
6-K
EX-99.1
cj8zx n616zxpt7a
10 Dec 19
ObsEva Announces Positive Results from Uterine Fibroids Phase 3 Study (PRIMROSE 2) of Linzagolix
12:00am